BioTrinity 2012: Company Showcase - Drug Discovery, Development and more
The BioTrinity 2012 Company Showcase is a unique opportunity to take in over 60 corporate/investor presentations from the best companies from Europe's most successful bioclusters and partner with them. Already companies from 8 countries are represented making the showcase more international than ever. This year we will again feature a mostly hand-selected line-up of the Most Promising Companies over April 24-26th 2012. Day one will feature drug discovery and development (oncology, CNS, anti-infectives, anti-virals) as well as platform technologies, and Day Two will feature more drug discovery, medtech as well as platform technology companies. For the first time, the Companies Presentation will be held in two parallel allowing a maximum of 70 companies to be showcased. Do contact our CEO, jon.rees@obn.org.uk soon if you wish to be considered for one of presention slots, and do read details of the Selection Process below.
Wednesday and Thursday, 25-26th April 2012
Day 1, Track 1, in "The Flats Room", Sponsored by Shire, Chaired by Sue Staunton, James Cowper LLP |
|
13:30 - 15:00 Oncology Track |
|
 |
13:40 Immunocore, James Noble, CEO |
 |
13:50 Scancell Holdings, Richard Goodfellow, Joint CEO |
 |
14:00 Saturn Biosciences, Nigel Courtenay-Luck, CSO |
 |
14:10 immatics biotechnologies GmbH, Paul Higham, CEO (Germany) |
 |
14:20 Debiopharm SA, Wilma Lukas, Senior Search & Evaluation Officer, In-Licensing (Switzerland) |
 |
14:30 BruCells SA/NV, Gilles M Capart, MD (Belgium) |
 |
14:40 Chroma Therapeutics, Ian Nicholson, CEO |
 |
14:50 Matos Pharma, Keyji Johnsen, CEO (Japan) |
15:30-16:00 Track: Oncology Platform |
|
 |
15:30 F-star GmbH, Jane Dancer COO (Austria) |
 |
15:40 Syntaxin, Melanie Lee, CEO |
 |
15:50 Domainex, Edward Littler, CEO |
 |
16:00 Horizon Discovery, Darrin Disley, CEO |
 |
16:10 Physiomics, Mark Chadwick, CEO |
16:20-17:30 Track: Discovery Platform and Service |
|
 |
16:20 SeaLife Pharma GmbH, Alexander Pretsch (Austria) |
 |
16:30 Antoxis, Andrew Porter, Director |
 |
16:40 InhibOx, Paul Davie, CEO |
|
16:50 Quy BioScience, Stephen Arnott, MD |
 |
17:00 Argenta, Jeremy Billson, VP Business Development |
 |
17:10 Syntecnos, Eric Wielhouwer, Director (Netherlands) |
 |
17:20 BRAINco, Julie Masse, Business Developer (Spain) |
Day 1, Track 2, in "The Jumps Room", Sponsored and Chaired by Shire, Chaired by David Colpman, Shire |
|
13:30 - 15:00 RegenMed and Medtech Track |
|
 |
13:20 Shire, David Colpman, Senior Vice President Business Development |
 |
13:30 Oxford Medical Diagnostics, Paul Harper, Chairman |
 |
13:40 FibromEd, Howard Marriage, Director |
 |
13:50 Oxford Biomaterials, Stephanie Lesage, COO |
 |
14:00 Oxtex, David Jackson, CEO |
 |
14:10 Videregen, Steve Bloor, CEO |
 |
14:20 Orthox, Nick Skaer, CEO |
 |
14:30 PlaqueTec, Richard Owen, CSO |
 |
14:40 Oval Medical Technologies, Catherine Beech, CEO |
 |
14:50 Glysure, Chris Jones, CEO |
Chaired by Patrick Baddeley, Manches15:30-16:40 Track: Inflammation and Immunity |
|
 |
15:30 MorphoSys AG, Anne Assmus, Manager Business Development (Germany) |
 |
15:40 IXO Therapeutics, Douglas Thomson, CEO |
 |
15:50 Avienne Pharmaceuticals GmbH, Burkhard Jansen, CEO (Austria) |
 |
16:00 Creabilis SA, David Roblin, Medical Director (Luxembourg) |
 |
16:10 Circassia, Steven Harris, CEO |
16:20-16:40 Track: Biomarkers |
|
 |
16:20 Oxford Gene Technology, Mike Evans, CEO |
 |
16:30 Cytox, Richard Pither, CEO |
16:40-17:20 Track: Other Therapeutics |
|
 |
16:40 arGEN-X BV, Debbie Allen, Senior Director Business Development |
 |
16:50 Critical Pharmaceuticals, Gareth King, CBO |
 |
17:00 MISSION Therapeutics, Niall Martin, COO |
 |
17:10 ProRetina Therapeutics, Stuart Medina, CEO (Spain) |
 |
17:20 Gallus BioPharmaceuticals, Mark Bamforth, CEO |
Day 2, Track 1, in "The Flats Room", Sponsored by Amgen, Chairperson To Be Announced |
|
13:25-16:00 Platform Technology and Service Track |
|
 |
13:25 Milton Park, James Dipple, MD |
 |
13:40 Kymab, Tom Shepherd, CBO |
 |
13:50 FINOX Biotech, Anjan Selz, CEO |
 |
14:00 Progenitor Labs, Yen Choo, CEO |
 |
14:10 Redx Pharma, Neil Murray, CEO |
 |
14:20 PolyTherics, Sally Waterman, COO |
 |
14:30 Amakem Therapeutics NV, Jack Elands, CEO (Netherlands) |
 |
14:40 Cyclofluidic, Dave Parry, COO |
 |
14:50 Selcia, Simon Saxby, CEO |
 |
15:00 InSphero AG, Jan Lichtenberg, CEO (Switzerland) |
 |
15:10 Biognosys, Yulia Butscheid, Head of Strategy & Business Development (Switzerland) |
|
15:20 Cardeus Pharmaceuticals, Inc., Karen Brunke, President and CEO (United States) |
 |
15:30 JPT Peptide Technologies GmbH, Paul von Hoegen, Senior Director, Business Development (Germany) |
|
15:40 APPLY TO PRESENT |
 |
15:50 Closing Remarks, Dr Jon Rees, CEO, OBN |
Day 2, Track 2, in "The Jumps Room", Sponsored by MSD, Chairperson To Be Announced |
|
13:30 - 14:50 Anti-infectives track: Anti-bacterials, anti-virals and vaccines |
|
 |
13:30 London Pharma, David Laskow-Pooley, CEO |
 |
13:40 Summit plc, Richard Pye, Head of Investor Relations and Communications |
 |
13:50 MGB BioPharma, Gavin Clark, CBO |
 |
14:00 Mucosis BV, Govert Schouten, CEO (Netherlands) |
 |
14:10 Absynth Biologics, Fiona Marston, CEO |
 |
14:20 Inocul8, Richard Mole, COO |
 |
14:30 Procarta Biosystems, David Knowles, Chairman |
 |
14:40 Oxford Pharmascience Group Ltd, Claire Thompson, Director of Pharma Development |
Chaired by Jayne McLaughlin, george james ltd14:50 - 16:00 Other Emerging Companies |
|
 |
14:50 Alchemy Pharmatech, Bruce Savage, CEO |
 |
15:00 Bionext, Serge Albou, CEO |
 |
15:10 ImmunNovative Developments, Josep Falco, CEO |
 |
15:20Crescent Diagnostics, Brendan Farrell, CEO |
 |
15:30Momentum Bioscience, Bill Mullen, CEO |
 |
15:40 Microvisk Limited, John Curtis, CEO |
|
15:50 OBN, Andy Smith, Director of Investor Relations and PR - Close |
Overview of the company showcase
The majority of companies were hand-selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. The focus is on drug discovery and development, diagnostics and medical technology. The format of the presentations is an 8 minute presentation, including Q&A. Click on each speaker name to read biographies - further speaker biographies will be added as we receive them.
Selection Process
The vast majority of companies listed above are hand-picked by our team, although a small number of slots are reserved for applicants. Please contact our CEO Jon Rees on +44 (0)845 5245 722 to discuss and apply for a speaking slot or make an Online Application. An informed decision will be made based upon information supplied by companies, business intelligence, potentially with reference to the expert knowledge of members of the OBN Advisory Board and our extended BioTrinity Advisory Board. As with other delegates, speakers from selected companies must complete a paid registration to be admitted and benefit from partnering at BioTrinity 2012.
Companies who are not selected to present are encouraged to participate in the one-to-one partnering elements of the meeting for the purposes of business development.
Criteria for Selection
- Consideration will be given to company's USP, or the USP of their leading product, the route-to-market, exit route and milestones.
- Consideration is given to revenue streams or demonstrated fund-raising ability, and proximity to market
- Efficient use of funding
- Recent deal-making success
- Innovation in product or business strategy
- Preference is given to companies based in the UK and Europe
- Preference is given to companies which have been trading for less than 7 years
- Intellectual property to meet business strategy
